Roche Provides Info About Ongoing HD Program & Announces Two Upcoming Trials; HDSA to Host Webinar
Posted on September 20, 2018
This past Sunday at the plenary meeting of the European Huntington’s Disease Network (EHDN), Roche Pharmaceuticals announced some details about…
Read MoreRegister for the Upcoming HDSA Webinar with Roche/Genentech on Wed. September 26th
Posted on September 13, 2018
This week, members of the HDSA team are attending the 2018 plenary meeting of the European Huntington’s Disease Network (EHDN)…
Read MoreInterview with 2018 Berman-Topper Fellow – Dr. Rachel Harding
Posted on September 6, 2018
This week, meet Dr. Rachel Harding from the University of Toronto, the recipient of this year’s Berman-Topper Family HD Career…
Read MoreHD Featured in Science Magazine
Posted on August 30, 2018
The prestigious Science magazine published an article on Huntington’s disease this week, describing the huntingtin-lowering ASO drug developed by Ionis,…
Read MoreProposal to Streamline Gene Therapy Evaluation by the FDA
Posted on August 23, 2018
This week, the FDA released a proposal to streamline the way they oversee the evaluation of protocols related to gene…
Read MoreFirst Gene-Silencing Drug Approved by the FDA
Posted on August 16, 2018
This week marked the first FDA approval of a gene silencing drug, for a rare hereditary disease called ATTR amyloidosis….
Read MoreRoche Huntingtin-Lowering Drug Gains PRIME Status from EMA
Posted on August 7, 2018
On August 4th, Roche Pharmaceuticals announced that their huntingtin-lowering therapy was granted PRIME status from the European Medicines Agency (EMA)….
Read MoreVoice Your Opinions About The Future Of CRISPR
Posted on August 2, 2018
Community research surveys are valuable ways for researchers to get input from HD patients, families and caregivers about a variety…
Read MoreAt-Home DNA Kits Require Caution
Posted on July 26, 2018
At-home DNA kits like 23 & Me are growing in popularity, and claim to provide information about your health and…
Read MorePipeline of Therapies for HD
Posted on July 19, 2018
The Rare Disease Report covers stories about medicine, finance, and advocacy in rare disease fields. Last week an article explored…
Read MoreDNA Repair Research Uncovers New Drug Targets
Posted on July 12, 2018
Researchers led by Ray Truant at McMaster University in Canada are investigating how DNA repair could help correct some of…
Read MoreResearch Highlights from the 33rd Annual HDSA Convention
Posted on July 5, 2018
As we ease into the summer, enjoy some highlights from our research sessions at HDSA’s 33rd Annual Convention in Los…
Read MoreHDSA’s 33rd Annual Convention Research Forum Video Now Available
Posted on June 14, 2018
HDSA’s 33rd Annual Convention in Los Angeles from June 7th-9th included the 2018 Research Forum, where ten speakers collaborated to tell…
Read MoreHDSA Convention Research Forum
Posted on June 7, 2018
This week we’re hosting the 33rd Annual HDSA Convention in Los Angeles, California. Tune in to the livestream of our Research Forum…
Read MoreHuntington’s Disease Featured in Nature Outlook
Posted on May 31, 2018
The prestigious journal Nature publishes both research reports and journalistic articles, and is widely read by scientists and non-scientists. This…
Read MoreParticipate in a Research Study at the HDSA Convention
Posted on May 24, 2018
If you are negative for the HD gene, currently participate in Enroll-HD, and will be attending HDSA’s Convention in June,…
Read MoreHDSA Announces 2018 Berman-Topper HD Career Development Fellowship Recipient
Posted on May 17, 2018
The 2018 HDSA Berman-Topper fellowship has been awarded to Dr. Rachel Harding for her proposal entitled “Structural and biophysical investigations…
Read MoreMay is HD Awareness Month
Posted on May 10, 2018
Join the #HDSAFamily as we turn up the global volume on HD awareness. Visit www.HDSA.org/letstalkaboutHD for more info. Don’t forget…
Read MorePositive Trends in Data from Ionis Huntingtin-Lowering Trial
Posted on May 3, 2018
On April 24th, 2018, Ionis Pharmaceuticals made an announcement about the Phase 1/2 clinical trial of their huntingtin-lowering drug, IONIS-HTTRx…
Read MoreIonis/Roche Present Trial Data at World’s Largest Neurology Conference
Posted on April 26, 2018
Huntington’s disease was featured this week at the American Academy of Neurology (AAN) Conference, where 12,000 medical professionals gathered for…
Read More